ArticleMycopathologia2026
Antifungal Susceptibility and Multilocus Sequence Typing of Pichia kudriavzevii (Candida krusei) from a Tertiary Hospital in Shanghai.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The incidence of infections by non-albicans Candida species, including Pichia kudriavzevii (formerly Candida krusei) has been increasing. P. kudriavzevii exhibits intrinsic resistance to fluconazole (FLU) and rapidly develops acquired resistance to other antifungals. However, large-scale epidemiological, antifungal susceptibility, and genotyping data from mainland China remain limited. We analyzed the clinical and laboratory data of 203 P. kudriavzevii isolates spanning from 2017 to 2023. In vitro antifungal susceptibility testing was performed by the Sensititre YeastOne microdilution method. The genotyping of P. kudriavzevii isolates was analysed by multilocus sequence typing (MLST). The results showed that P. kudriavzevii were predominantly isolated from sputum (132, 65.02%) and urine (21, 10.34%). Patients with P. kudriavzevii isolation were mainly from the Infectious Diseases Department (50, 24.63%), Intensive Care Unit (lCU) (45, 22.17%) and General Surgery (32, 15.76%), and the pathogen was highly prevalent in individuals over 60 years old. All isolates exhibited intrinsic resistance to FLU. The resistance rate to voriconazole (VOR) was 9.4% (19/203), showing an increasing trend. 80 isolates (39.41%) were non-wild-type (NWT) to amphotericin B (AMB) and posaconazole (POS). Excluding FLU, 31 isolates (15.27%) exhibited a resistant or NWT phenotype to at least two distinct antifungal agent classes, and the MLST analysis of them revealed 16 distinct diploid sequence types (DST) profiles. Among these, ST195 (7, 22.6%) and ST268 (6, 19.4%) were the predominant genotypes associated with antifungal resistance, and 58.1% of the resistant sequence types exhibited resistance to VOR. Continuous monitoring of antifungal susceptibility and molecular typing is essential. This study provides valuable insights for managing P. kudriavzevii infections and guiding clinical treatment strategies.
Indexed as
Identifiers
41790340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.